Healthcare
Oracle and AstraZeneca target clinical-trial bottlenecks with AI
Oracle and AstraZeneca are exploring AI and health data for clinical-trial recruitment and evidence generation across several disease areas and regions.
Oracle and AstraZeneca plan to explore AI-enabled applications that help clinicians identify patients eligible for clinical trials, accelerate evidence generation, and bring research insights into everyday care. The collaboration combines Oracle’s health-data, cloud, AI, analytics, and workflow capabilities with AstraZeneca’s scientific and therapeutic expertise. Disease areas under consideration include oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology conditions, and rare diseases. The agreement is non-binding, and the companies describe it as an exploration of selected use cases rather than a completed commercial platform. Its importance lies in targeting clinical-trial recruitment, a process that often requires extensive manual review of patient records and eligibility criteria. AI-assisted identification could reduce the time needed to locate candidates and potentially expand access to trials. The project also reflects a wider healthcare technology trend: integrating artificial intelligence into existing clinical workflows and longitudinal data rather than using it only for standalone diagnosis. The first program is in Abu Dhabi with M42, but the companies describe the collaboration as international, with further projects expected across multiple regions.
Original source: Oracle